Athira Pharma is a Seattle, WA-based clinical-stage drug development company advancing first-in-class regenerative therapies aimed at restoring brain function. Led by Dr. Leen Kawas, the company is advancing its lead therapeutic candidate, NDX-1017, a novel small molecule in later-stage clinical trials for Alzheimer’s. Athira describes its approach as bold and innovative therapies to improve human health for people impacted by brain disorders. The company intends to use newly raised funds to support a Phase 2/3 Alzheimer’s clinical trial of NDX-1017. The article does not provide operating metrics such as revenue or user numbers. M3 Biotechnology is a Seattle-based therapeutics company developing small-molecule treatments for Alzheimer’s disease. The company focuses on re-establishing lost connections between brain cells to improve cognitive function. Led by CEO Leen Kawas, M3’s lead candidate is NDX-1017. The company is planning a first-in-humans Phase 1a clinical trial to evaluate NDX-1017’s safety and dosing. M3 raised $1.4M in a second funding round and has secured $14M in total financing to date. Proceeds from the latest round will support the launch of human trials, with backers including Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation.

Total raised

$86M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2020